What is the SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) for systemic lupus erythematosus (SLE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is SLEDAI for SLE?

SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) is a validated, weighted scoring tool that quantifies disease activity in SLE patients, with scores ranging from 0 to 105, used to monitor disease progression, assess treatment response, and guide therapeutic decisions in both clinical practice and research settings 1.

Core Structure and Scoring

SLEDAI assigns weighted scores to 9 organ systems based on their clinical importance:

  • Weight of 8: Central nervous system and vascular manifestations
  • Weight of 4: Renal and musculoskeletal involvement
  • Weight of 2: Serosal, dermal, and immunologic features
  • Weight of 1: Constitutional and hematologic abnormalities

The maximum theoretical score is 105, though in practice few patients exceed 45 2.

Clinical Interpretation

Disease activity levels correlate with SLEDAI scores as follows:

  • Remission: SLEDAI = 0
  • Low disease activity: SLEDAI ≤3-4 (when on antimalarials with prednisone ≤7.5 mg/day)
  • Moderate activity: SLEDAI 2-8
  • Severe activity: SLEDAI >9.90 (based on recent validation) 3, 4

Clinically meaningful changes:

  • Flare: Increase in SLEDAI >3
  • Improvement: Decrease in SLEDAI >3
  • Stable disease: Change in SLEDAI ±3 5

Validated Modifications

Several validated versions exist for specific contexts 1:

  • SLEDAI-2K: Modified to capture persistent active disease (not just new/recurrent), particularly for rash, mucous membranes, alopecia, and proteinuria—suitable for clinical trials 6
  • SELENA-SLEDAI: Used in the Safety of Estrogens in Lupus National Assessment studies
  • SLEDAI-2KG: Incorporates glucocorticoid doses into disease activity assessment

Clinical Utility and Validation

SLEDAI demonstrates strong clinical performance:

  • High inter-observer reliability (78.7% agreement) even among less experienced clinicians 7
  • Excellent intra-observer agreement (98.0%) 7
  • Validated predictor of mortality 6
  • Sensitive to change over time, outperforming other indices like SLAM and BILAG in detecting disease activity changes 8
  • Correlates with physician global assessment and treatment decisions 5

Practical Application

In routine monitoring, SLEDAI should be used alongside:

  • Anti-dsDNA antibodies and complement levels (C3/C4)
  • Organ-specific assessments (proteinuria, blood pressure, urinalysis for renal involvement)
  • Physician Global Assessment (PGA) for comprehensive evaluation 1, 9

Treatment targets based on SLEDAI:

  • Aim for remission (SLEDAI = 0) or low disease activity (SLEDAI ≤3-4)
  • These targets associate with reduced damage accrual, fewer flares, and better long-term outcomes 3, 10

Important Caveats

SLEDAI has limitations:

  • Does not measure accumulated organ damage (use SLICC/ACR Damage Index for this purpose) 1
  • May not fully capture certain manifestations like chronic cutaneous lupus or some neuropsychiatric features
  • Some patients show serological activity without clinical disease ("serologically active, clinically quiescent SLE") 1
  • SLE-DAS (an alternative scoring system) may provide better correlation with severe thrombocytopenia and cardiopulmonary involvement 11

For lupus nephritis specifically, response assessment requires additional parameters beyond SLEDAI, including proteinuria reduction to <0.5-0.8 g/day and stabilization of serum creatinine 9.

References

Research

Systemic lupus erythematosus disease activity index 2000.

The Journal of rheumatology, 2002

Related Questions

How should I interpret a SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score?
What pulmonary manifestations can occur in systemic lupus erythematosus?
Can a nephrologist clear a 42‑year‑old woman with primary hepatic cholangiocarcinoma, rectal adenoma, pancreatic‑tail tumor, active lupus nephritis, systemic lupus erythematosus, scleroderma, inflammatory myopathy, and impaired renal function (serum creatinine 2.9 mg/dL) for treatment with capecitabine, atezolizumab, bevacizumab (Avastin), durvalumab (Imfinzi), and tremelimumab (Imjudo)?
In a 25-year-old woman with four months of fatigue, myalgia, arthralgia, recent weight loss, decreased appetite, a 3‑cm circular patch of scalp hair loss, and scaly erythematous facial plaques, which initial laboratory study is most appropriate to determine the diagnosis?
Which antidepressants should be avoided or used with caution in patients with systemic lupus erythematosus?
What low‑potency topical steroid regimen is recommended for treating an eyelid rash?
Is it safe to take ketorolac (Toradol) and lorazepam (Ativan) together?
When should a peripherally inserted central catheter (PICC) line be heparin locked?
What does current research show about the efficacy, dosing, safety, and clinical applications of Lactobacillus plantarum PS128?
What is the appropriate dose of cefalexin (Keflex) for a 13.3‑kg child at 40 mg/kg/day using a suspension that contains 250 mg per 5 mL?
What are the interactions between metoclopramide and bupropion?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.